GaBI Journal-Generics and Biosimilars Initiative Journal
metrics 2024
Connecting Professionals in Pharmaceutical Science
Introduction
GaBI Journal - Generics and Biosimilars Initiative Journal, published by PRO PHARMA COMMUNICATIONS INT, serves as a pivotal platform for the dissemination of research and developments in the field of generics and biosimilars. Since its inception in 2014, this journal has established itself as an essential resource for healthcare professionals, researchers, and students dedicated to understanding the complexities of drug regulation and therapeutic equivalence. With an impressive recognition in the Scopus rankings—placing #2 out of 5 in Drug Guides and #20 out of 45 in Pharmacy—it is focused on fostering innovation and enhancing pharmaceutical practices. The journal is indexed with a current impact factor that reflects its significant contributions to the literature, making it a vital reference for those seeking to make advancements in pharmaceutical sciences. While currently not an open-access journal, it aims to support ongoing educational and professional growth in a rapidly evolving industry, ensuring that readers stay informed on the latest developments and research in generics and biosimilars.
Metrics 2024
Metrics History
Rank 2024
Scopus
IF (Web Of Science)
JCI (Web Of Science)
Quartile History
Similar Journals
Universitas Medica
Illuminating the path to medical advancements and education.Universitas Medica is a prominent journal dedicated to advancing the field of medical sciences, published by the Pontificia Universidad Javeriana, Facultad de Medicina. Since its transition to an Open Access format in 2010, it has played a pivotal role in promoting the dissemination of high-quality medical research. Featuring a diverse array of studies encompassing clinical practice, public health, and medical education, Universitas Medica aims to provide researchers, healthcare professionals, and students with invaluable insights and the latest findings in medicine. With a focus on enhancing accessibility and fostering collaboration across the medical community, this journal stands out as a critical resource for those looking to stay abreast of innovations and trends. The journal is indexed under ISSN 0041-9095 and E-ISSN 2011-0839 and operates from its base in Bogotá, Colombia, contributing significantly to the scientific landscape both regionally and internationally.
DRUGS & THERAPY PERSPECTIVES
Exploring Innovative Pathways in Drug EfficacyDRUGS & THERAPY PERSPECTIVES is an esteemed journal published by SpringerNature, dedicated to advancing knowledge in the field of pharmacology and therapeutic studies. With an ISSN of 1172-0360 and an E-ISSN of 1179-1977, this journal has been providing valuable insights since its inception in 1993 and continues to publish until 2024. Ranked in the Q3 category for Pharmacology (medical) and positioned within the 25th percentile according to Scopus rankings, it serves as a vital resource for researchers, practitioners, and students alike. Although it is not an open-access journal, it offers a comprehensive platform for innovative research, clinical practices, and evolving therapeutic strategies, reflecting the critical developments in drug therapy landscape. With its strategic emphasis on bridging academic studies and clinical applications, DRUGS & THERAPY PERSPECTIVES remains essential for those committed to enhancing drug efficacy and patient outcomes in the ever-evolving medical field.
Journal of Pioneering Medical Sciences
Transforming medical practice with innovative findings.Journal of Pioneering Medical Sciences, published by JPMS PUBL in Karachi, Pakistan, stands as a vital resource in the field of medical research and practice. Established in 2012, this Open Access journal fosters the dissemination of innovative findings and groundbreaking studies that contribute to the advancement of medical science. With an ISSN of 2309-7981 and a commitment to rigorous peer-review, the journal encompasses a diverse range of topics, aiming to bridge knowledge gaps and promote interdisciplinary dialogue among healthcare professionals and researchers. Although it currently lacks an H-index, its focus on pioneering medical studies positions it as a platform for impactful contributions that can shape future healthcare policies and practices. The journal's open access policy ensures that vital research is freely available to a global audience, promoting accessibility and collaboration in the medical community.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
Exploring the Frontiers of Pharmacology and ToxicologyThe European Journal of Pharmaceutical Sciences is a prestigious academic journal dedicated to advancing the field of pharmaceutical science. Published by Elsevier, the journal boasts an impressive impact factor and is categorized in the Q1 quartile for pharmaceutical science as of 2023, signifying its influence and reputation within the academic community. With a Scopus ranking of #20 out of 183 in the fields of pharmacology, toxicology, and pharmaceutics, the journal provides a vital platform for researchers and practitioners to disseminate innovative studies and groundbreaking research that push the boundaries of drug development and delivery. Based in the Netherlands and operating since 1993, the journal seeks to cover a broad scope of topics related to pharmaceutical sciences, encouraging rigorous evaluations and discussions that enhance the understanding and application of this critical field. The absence of open access underscores the commitment to maintaining high scholarly standards, while still offering avenues for libraries and institutions to provide access to cutting-edge research. As the journal converges towards its 2024 milestones, it continuously aims to foster a vibrant exchange of knowledge among its diverse readership, comprising committed researchers, professionals, and students.
Nobel Medicus
Catalyzing Change in the World of Medical Research.Nobel Medicus, published by NOBEL ILAC, is a Turkish academic journal that has been contributing to the field of medicine since its inception in 2005. With an ISSN of 1305-2381, this journal focuses on a broad spectrum of medical research, catering to both clinical and academic professionals. Although currently positioned in the Q4 quartile for miscellaneous medicine according to 2023 category rankings, the journal aims to promote innovative and impactful studies, providing a platform for promising research within a competitive landscape. The journal's commitment to accessibility for the global research community is critical, even in the absence of open access options. Placed in the 7th percentile with a Scopus rank of #586 out of 636 in the general medicine category, it seeks to grow in influence and visibility. As such, Nobel Medicus plays an important role in disseminating valuable medical insights, fostering connections among researchers, healthcare professionals, and emerging scholars in the field.
DRUGS
Catalyzing Progress in Pharmacology and MedicineDRUGS is a prestigious, peer-reviewed journal published by ADIS INT LTD, specializing in the field of pharmacology across diverse medical applications. With an impressive impact factor and ranking as Q1 in the Pharmacology (Medical) category as per the 2023 metrics, this journal consistently exhibits a strong influence in the medical research community, holding a notable rank of #3 out of 272 in its domain on Scopus, placing it within the 99th percentile. Established in 1971 and converging its insightful contributions until 2024, DRUGS encompasses a broad scope, focusing on the latest advancements in drug research, development, and clinical applications, aiming to bridge the gap between laboratory discoveries and therapeutic practices. Though not an Open Access journal, it remains a key resource for researchers, professionals, and students keen on exploring cutting-edge findings and developments in pharmacology. Its location in the United Kingdom further emphasizes its role as a global leader in pharmaceutical sciences.
Clinical Pharmacology-Advances and Applications
Catalyzing Collaboration for Pharmacological ExcellenceClinical Pharmacology-Advances and Applications is a premier open access journal published by DOVE MEDICAL PRESS LTD, based in New Zealand. Since its establishment in 2009, the journal has been dedicated to advancing the field of pharmacology by disseminating innovative research and applications related to medication therapy and patient outcomes. With its notable impact factor and current ranking within the top percentile of pharmacology journals, it provides an invaluable platform for researchers, healthcare professionals, and students to share knowledge and foster collaboration. The journal's content spans a wide range of topics, ensuring coverage of both fundamental and emerging areas in medical pharmacology. As of 2023, it holds a strong position in the Q2 quartile, underscoring its relevance and influence within the scientific community. Authors and readers alike benefit from its open access model, which ensures that critical findings are widely accessible, thereby enhancing the pace of discovery and application in clinical settings.
THERAPEUTIC DRUG MONITORING
Enhancing Drug Efficacy with Rigorous Research InsightsTHERAPEUTIC DRUG MONITORING, published by Lippincott Williams & Wilkins, is a prestigious journal that focuses on the critical area of pharmacology, with a specific emphasis on the therapeutic optimization of drug therapy. With an ISSN of 0163-4356 and an E-ISSN of 1536-3694, this peer-reviewed journal has been contributing valuable research and insights to the field since its inception in 1979. As of 2023, it holds a Q2 classification in the Pharmacology category, indicating its prominent role in advancing pharmaceutical sciences. The journal aims to enhance understanding of drug effectiveness and safety through rigorous studies on drug monitoring and individualized therapy, making it an essential resource for researchers, healthcare professionals, and students dedicated to improving patient care. With its solid standing reflected in Scopus rankings, including a rank of #103 in medical pharmacology and a 62nd percentile, THERAPEUTIC DRUG MONITORING continues to be a vital publication for those aiming to contribute to and stay informed about the latest developments in the field.
AMERICAN JOURNAL OF THERAPEUTICS
Transforming Patient Care with Cutting-Edge InsightsThe American Journal of Therapeutics is a prominent academic journal published by Lippincott Williams & Wilkins, specializing in the fields of medicine and pharmacology. With a rich history originating from 1960 and a commitment to advancing therapeutic knowledge through peer-reviewed research, this journal serves as a vital resource for professionals, researchers, and students alike. Its strong impact factor, alongside its classification in the Q2 and Q3 quartiles for diverse categories in medicine and pharmacology, underscores its significance in the academic community. The journal engages with the latest findings and innovations in therapeutic approaches, offering a platform for discussion and dissemination of research that addresses critical healthcare challenges. Although it operates under a traditional subscription model, the journal aims to foster open discourse within the therapeutic landscape, making it essential reading for those dedicated to enhancing patient care and pharmaceutical practices.
Pharmacy
Exploring the frontiers of pharmaceutical sciences without barriers.Pharmacy is a premier open-access journal published by MDPI, dedicated to advancing research in the dynamic field of pharmaceutical sciences. Since its inception in 2013, this journal has become a vital platform for disseminating novel findings, reviews, and insights related to drug development, pharmacokinetics, pharmaceutical technology, and clinical applications. With an E-ISSN of 2226-4787, Pharmacy prioritizes accessibility and visibility, allowing researchers, professionals, and students from around the globe to engage with cutting-edge research without barriers. The journal plays a crucial role in shaping pharmaceutical education and practice, fostering innovative ideas and collaborative approaches aimed at improving health outcomes. As part of the MDPI family, Pharmacy is committed to maintaining high-quality standards, ensuring that all published articles undergo rigorous peer review.